TG Therapeutics Inc (NASDAQ:TGTX) has received a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.80.

Several research analysts have recently weighed in on the company. B. Riley reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Tuesday. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. ValuEngine cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $17.00 price objective on shares of TG Therapeutics in a research report on Monday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of TG Therapeutics in a research report on Friday, April 12th.

A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Great Point Partners LLC boosted its position in TG Therapeutics by 53.8% during the fourth quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $12,300,000 after purchasing an additional 1,050,000 shares during the last quarter. Opaleye Management Inc. boosted its position in TG Therapeutics by 148.4% during the first quarter. Opaleye Management Inc. now owns 1,366,062 shares of the biopharmaceutical company’s stock valued at $10,983,000 after purchasing an additional 816,062 shares during the last quarter. Two Sigma Investments LP boosted its position in TG Therapeutics by 312.9% during the fourth quarter. Two Sigma Investments LP now owns 769,011 shares of the biopharmaceutical company’s stock valued at $3,153,000 after purchasing an additional 582,771 shares during the last quarter. venBio Select Advisor LLC boosted its position in TG Therapeutics by 13.1% during the fourth quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after purchasing an additional 549,969 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in TG Therapeutics by 72.2% during the fourth quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock valued at $3,378,000 after purchasing an additional 345,477 shares during the last quarter. 54.60% of the stock is owned by hedge funds and other institutional investors.

TGTX stock opened at $7.26 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.72 and a current ratio of 1.72. TG Therapeutics has a fifty-two week low of $3.32 and a fifty-two week high of $14.65.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.01. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. As a group, research analysts expect that TG Therapeutics will post -1.58 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

See Also: How does inflation affect different investments?

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.